Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
Support Care Cancer ; 27(6): 2095-2102, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-30229339

RESUMO

Prognostic characterization in the initial assessment of patients with advanced cancer disease is an essential step to plan the most appropriate therapeutic program. Since clinical prediction of survival (CPS) may be of limited value, some authors have tried to integrate specific prognostic factors into prognostic multidimensional scores. We carried out a prospective cohort study in two palliative care units to compare the accuracy of the Palliative Prognostic (PaP) Score, the Objective Prognostic Score (OPS), and the Palliative Prognostic Index (PPI). In addition, we compared the accuracy of the CPS independently estimated by different healthcare professionals and we tested the role of laboratory results, together with clinical and social factors in predicting survival. Clinical and laboratory data of 334 advanced cancer patients were prospectively collected from the time of in-hospital admission. PaP Score was the most accurate index of survival prediction, followed by PPI; CPS estimates' accuracy was similar among physicians and nurse. All healthcare professionals tended to underestimate the real survival. Integrating CPS with multidimensional indexes may further improve the patient's management. The degree of autonomy and the number of metastatic sites were independent prognostic factors for 30-days mortality and overall survival in multivariate analysis.


Assuntos
Neoplasias/terapia , Cuidados Paliativos/métodos , Adulto , Idoso , Estudos de Coortes , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias/mortalidade , Neoplasias/patologia , Prognóstico , Estudos Prospectivos
2.
J Cancer Res Clin Oncol ; 144(10): 2029-2047, 2018 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-30043280

RESUMO

BACKGROUND: It is estimated that about half of cancer patients use at least one form of complementary and alternative medicines (CAM) in their life but there is a strong reticence of patients in talking about CAM with their oncologist. Primary aim of this study was to inform patients about CAM, focusing on their supposed benefits, toxicities and interactions with conventional therapeutic agents. The study also explored patients' perception about CAM and ascertained the level of CAM use among cancer patients of an Italian academic hospital. METHODS: From April 2016 to April 2017, the observational pilot trial "CAMEO-PRO" prospectively enrolled 239 cancer patients that were invited to attend a tutorial about CAM at the Department of oncology, University Hospital of Udine, Italy. Before and after the informative session, patients were asked to fill a questionnaire reporting their knowledge and opinion about CAM. RESULTS: Overall, 163 (70%) women and 70 (30%) men were enrolled. Median age was 61 years. At study entry, 168 (72%) patients declared they had never been interested in this topic previously; 24 patients (11%) revealed the use of a type of alternative therapy and 58 (28%) revealed the use of complementary therapy. In total, 139 (55.2%) patients attended the informative session. Bowker's test of symmetry demonstrated statistically significant opinion's change after the session on 9 out of 14 explored items. CONCLUSIONS: Informative sessions seem to have a relevant impact on patients' perceptions and opinions about CAM.


Assuntos
Terapias Complementares/estatística & dados numéricos , Conhecimentos, Atitudes e Prática em Saúde , Neoplasias/tratamento farmacológico , Neoplasias/psicologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Percepção , Projetos Piloto , Prognóstico , Estudos Prospectivos , Inquéritos e Questionários , Adulto Jovem
3.
Expert Opin Biol Ther ; 17(3): 365-374, 2017 03.
Artigo em Inglês | MEDLINE | ID: mdl-28092723

RESUMO

INTRODUCTION: The mechanism of action of pertuzumab, a recombinant anti-HER2 humanized monoclonal antibody, is complementary to trastuzumab's. On 8 June 2012, the Food and Drug Administration approved the combination of pertuzumab with trastuzumab and docetaxel as first-line treatment of HER2-positive metastatic breast cancer. Furthermore, pertuzumab is the first drug to be approved in the neoadjuvant setting using a pathological complete response as an endpoint. Areas covered: The review provides insights into the main mechanisms of action of pertuzumab. In addition, it gives complete coverage of the landmark clinical and translational trials for this agent. Expert opinion: The new therapeutic algorithm in the treatment of HER2-positive advanced disease and the awaited results of the Aphinity trial are expected to impact the sequence of anti-HER2 treatment. Accordingly, the value of pertuzumab beyond progression needs to be properly studied. Furthermore, to improve the toxicity profile and efficacy of future treatment, new pertuzumab-based regimens are being investigated.


Assuntos
Anticorpos Monoclonais Humanizados/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Receptor ErbB-2/antagonistas & inibidores , Animais , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Mama/genética , Neoplasias da Mama/metabolismo , Feminino , Humanos , Receptor ErbB-2/genética , Receptor ErbB-2/metabolismo , Estados Unidos
4.
Future Oncol ; 13(3): 233-248, 2017 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-27615389

RESUMO

AIM: The present survey investigates the views of medical oncologists, general practitioners (GPs) and patients about the various surveillance strategies. METHODS: An online survey was conducted in Italy on a population of 329 medical oncologists, 380 GPs and 350 patients. RESULTS: Most of GPs (n = 291; 76%) claim that follow-up should be provided by the collaboration between GPs and medical oncologists. Most medical oncologists report to have a poor relationship with GPs (n = 151; 46%) or no relationships at all (n = 14; 4%). Most patients believe there is no real collaboration between medical oncologists and GPs (n = 138; 54%). CONCLUSION: GPs, medical oncologists and patients share the idea that the collaboration between oncologists and GPs for surveillance of cancer survivors is poor and should be improved.


Assuntos
Atenção à Saúde , Clínicos Gerais , Neoplasias/epidemiologia , Oncologistas , Sobreviventes , Atitude do Pessoal de Saúde , Feminino , Conhecimentos, Atitudes e Prática em Saúde , Humanos , Itália/epidemiologia , Masculino , Inquéritos e Questionários
5.
Crit Rev Oncol Hematol ; 98: 137-46, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-26657667

RESUMO

Hepatitis B virus (HBV) infection is a worldwide disease associated with significant morbidity and mortality and after acute infection, HBV infection can persist in about 1-2% of immunocompetent hosts. Chemotherapy-induced immunosuppression can lead to HBV reactivation and may cause discontinuation of anticancer treatment, fulminant hepatitis with liver failure and death. During immunosuppressive treatments such as chemotherapy, reactivation of HBV infection is a life-threatening complication that can occur in HBV active or inactive carriers but also in patients with OBI. Occult HBV infection (OBI) is defined as the presence of detectable very low levels of HBV DNA in HBsAg-negative patients. Many literature data showed a benefit from prophylactic antiviral treatment in cancer patients at risk for HBV reactivation, however there is no evidence in determining the benefit of routine screening for chronic HBV infection in all patients undergoing cytotoxic and immunosuppressive chemotherapy. Major guidelines recommend HBV screening in HBV-infection high risk patients or if the immunosuppression caused by the treatment is expected to be high.


Assuntos
Hepatite B/complicações , Hepatite B/terapia , Neoplasias/complicações , Neoplasias/terapia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Comorbidade , Hepatite B/diagnóstico , Hepatite B/epidemiologia , Vírus da Hepatite B/fisiologia , Humanos , Terapia de Imunossupressão/efeitos adversos , Imunossupressores/uso terapêutico , Neoplasias/epidemiologia , Neoplasias/virologia , Ativação Viral/efeitos dos fármacos , Ativação Viral/fisiologia
6.
Expert Rev Clin Pharmacol ; 8(2): 251-65, 2015 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-25597501

RESUMO

Since angiogenesis plays an important role in cancer growth, infiltration and metastasis, many agents targeting this pathway have been developed over the last decade. Antiangiogenic drugs interfere with this process and may inhibit neoplastic growth or induce tumor dormancy by blocking the expanding network of newly formed capillaries. Despite the initial promise, targeting angiogenesis in breast cancer has not reached major breakthroughs. Nevertheless, the immunologic role of VEGF deserves to be further explored. We aim to describe the biological mechanisms which underlie the role of angiogenesis in breast cancer carcinogenesis, to depict its contribution to the metastatic process and to review the most important clinical trials testing angiogenic inhibitors in breast cancer, including monoclonal antibodies and novel small molecules.


Assuntos
Inibidores da Angiogênese/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Neovascularização Patológica/tratamento farmacológico , Inibidores da Angiogênese/farmacologia , Animais , Anticorpos Monoclonais/farmacologia , Anticorpos Monoclonais/uso terapêutico , Antineoplásicos/farmacologia , Antineoplásicos/uso terapêutico , Neoplasias da Mama/irrigação sanguínea , Neoplasias da Mama/patologia , Desenho de Fármacos , Feminino , Humanos , Metástase Neoplásica/patologia , Neovascularização Patológica/patologia , Fator A de Crescimento do Endotélio Vascular/imunologia
7.
Recenti Prog Med ; 106(12): 601-7, 2015 Dec.
Artigo em Italiano | MEDLINE | ID: mdl-26780069

RESUMO

The role of Complementary and Alternative Medicine (CAM) treatments in oncology has always been heavily debated. It is estimated that about half of cancer patients experience at least one form of CAM through their life and because of the growing spread of these on the internet, the proportion is destined to grow. There is no clear distinction between alternative and complementary treatment due to the possibility to use the same remedy both alongside and instead of traditional therapies. The use of CAM may expose the patients to a wide spectrum of risks that may range from under treatment due to the delay in using official medicine treatment, to toxicities derived both as a direct consequence of the alternative molecule or because of drug interaction with conventional treatments. Because of the uncertainty regarding the risk-benefit ratio and the fact that the patients often do not declare their use if no specifically requested, this topic is relevant for physicians. Aim of this review is to cover the preeminent CAM, their supposed benefits, toxicities and interactions with conventional therapeutic agents.


Assuntos
Terapias Complementares/métodos , Neoplasias/terapia , Antineoplásicos/uso terapêutico , Terapias Complementares/efeitos adversos , Interações Medicamentosas , Humanos
8.
Expert Opin Drug Saf ; 13(2): 139-50, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24073801

RESUMO

BACKGROUND: Analysis of relative importance of side effects of anticancer therapy is extremely useful in the process of clinical decision making. There is evidence that patients' perception of the side effects of anticancer treatments changes over time. OBJECTIVES: Aim of this study was to evaluate the cancer patients' perceptions of physical and non-physical side effects of contemporary anticancer therapy. Four hundred and sixty-four patients entered the study (153 men and 311 women). Participants were asked to rank their side effects in order of distress by using two sets of cards naming physical and non-physical effects, respectively. Influencing factors, including treatment and patient characteristics, were also analysed. RESULTS: Patients ranked the non-physical side effect 'Affects my family or partner' first. 'Constantly tired' and 'Loss of hair' were ranked second and third, respectively. Significant differences from previous studies on this topic emerged. In particular, 'Vomiting', a predominant concern in previous studies, almost disappeared, whereas 'Nausea' and 'Loss of hair' remained important side effects in the patients' perception. Interestingly, marital status was predominant in driving patients' perception, being associated with several side effects ('Constantly tired', 'Loss of appetite', 'Affects my work/Home duties', 'Affects my social activities', 'Infertility'). Other significant factors influencing patient's perception of side effects included age, disease characteristics and ongoing anticancer therapy. CONCLUSIONS: This study provided information on current status of patients' perceptions of side effects of anticancer treatment. These results could be used in pre-treatment patient education and counselling.


Assuntos
Antineoplásicos/efeitos adversos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Percepção , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Náusea/induzido quimicamente , Vômito/induzido quimicamente
9.
Endocr Relat Cancer ; 21(1): R51-65, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24292601

RESUMO

Breast cancer is the most common invasive cancer in women of reproductive age. In young women, chemotherapy may induce amenorrhea: it is still uncertain how to assess menopausal status in these patients despite the importance of its definition for choosing appropriate endocrine treatment. In the development of sensitive biomarkers for fertility and ovarian reserve, anti-Müllerian hormone (AMH) is considered a promising marker of ovarian reserve. The clearest data regarding a clinical use of AMH are related to the measurement of the ovarian pool in women who undergo IVF: the available data, also in breast cancer patients, seem to suggest that AMH measurement, before gonadotropin administration, can be a useful marker for the prediction of women at risk for poor-response or no response to ovarian stimulation. The utility of AMH as a potential marker of chemotherapy-induced ovarian follicular depletion and an early plasma marker of chemotherapy-induced gonadal damage has been evaluated both in young women after treatment for cancer in childhood and in young survivors of hematological malignancies and solid tumors. Several studies have demonstrated a potential utility of AMH, inhibin, or follicle-stimulating factor as biomarkers predicting infertility risk in breast cancer patients, but the studies conducted so far are not conclusive. Further studies are needed in order to define the regimen-specific action of chemotherapy on AMH levels, the percentage of post-treatment recovery of plasma levels of the hormone, and the relationship between menopausal status and AMH.


Assuntos
Hormônio Antimülleriano/sangue , Biomarcadores Tumorais/sangue , Neoplasias da Mama/sangue , Neoplasias da Mama/fisiopatologia , Folículo Ovariano/fisiopatologia , Antineoplásicos/efeitos adversos , Antineoplásicos/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Estradiol/sangue , Feminino , Hormônio Foliculoestimulante/sangue , Humanos , Inibinas/sangue
10.
Womens Health (Lond) ; 9(6): 583-93, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24161310

RESUMO

Primary anticancer therapy is currently accepted as a therapeutic option for patients with early-stage breast cancer. Its objectives are to increase the chance of achieving a conservative surgery and, similar to adjuvant chemotherapy, to reduce the risk of distant recurrence. The prognostic significance of obtaining a pathological complete response has been evaluated in several randomized clinical trials and meta-analyses. Growing evidence suggests that pathological complete response may act as a valid predictor of overall survival. Of note, a significant association between pathological complete response and outcome has especially been observed in patients with HER2-positive and triple-negative (hormonal receptors negative and HER2-negative) breast cancer. This review focuses on recent trials of neoadjuvant treatment with specific attention to HER2-negative disease.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Mama/terapia , Quimioterapia Adjuvante , Mastectomia Segmentar , Terapia Neoadjuvante , Recidiva Local de Neoplasia/prevenção & controle , Feminino , Humanos , Prognóstico
11.
Clin Breast Cancer ; 13(3): 167-72, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-23218471

RESUMO

Thymidine phosphorylase (TP) expression has been found to be elevated in various solid tumors where it is likely involved in mechanisms that regulate cell proliferation, apoptosis, and angiogenesis. Based on these properties, it is tempting to hypothesize a potential prognostic role of TP, suggesting that a high TP expression could predict a poor outcome. On the other hand, TP expression has been studied for its role in predicting benefit from treatment with fluoropyrimidine-containing chemotherapy. Several studies have been conducted on breast cancer. The current evidence on the value of TP is not mature enough to allow its translation into clinical practice. However, several findings support the potentially predictive role of TP. In this light, TP appears to be a promising marker that can give helpful information to predict the benefit from capecitabine-based chemotherapy in patients with breast cancer.


Assuntos
Antimetabólitos Antineoplásicos/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Desoxicitidina/análogos & derivados , Fluoruracila/análogos & derivados , Timidina Fosforilase/metabolismo , Biomarcadores/metabolismo , Neoplasias da Mama/metabolismo , Capecitabina , Desoxicitidina/uso terapêutico , Feminino , Fluoruracila/uso terapêutico , Humanos , Prognóstico , Timidina Fosforilase/biossíntese
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...